Seminars in Hematology
Volume 45, Issue 3 , Pages 181-188 , July 2008

Interpretation of Associations in Pharmacoepidemiology

  • David W. Kaufman

      Affiliations

    • Corresponding Author InformationAddress correspondence to David W. Kaufman, ScD, Slone Epidemiology Center at Boston University, 1010 Commonwealth Ave, Boston, MA 02215.

References 

  1. Lubran MM. Hematologic side effects of drugs. Ann Clin Lab Sci. 1989;19:114–121
  2. Young NS, Alter BP. Aplastic Anemia, Acquired and Inherited. Philadelphia, PA: Saunders; 1994;
  3. Yunis AA. Chloramphenicol toxicity: 25 years of research. Am J Med. 1989;87:44N–48N
  4. Trevett AJ, Naraqi S. Saint or sinner? (A look at chloramphenicol). PNG Med J. 1992;35:210–216
  5. Kaufman DW, Kelly JP, Jurgelon JM, Anderson T, Issaragrisil S, Wiholm BE, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol. 1996;60(suppl):23–30
  6. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869–874
  7. Andersohn F, Konzen C, Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146:657–665
  8. Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets—1960 to 1999. Drug Inform J. 2001;35:293–317
  9. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ. 2005;172:765–767
  10. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: The importance of reporting suspected reactions. Arch Intern Med. 2005;165:1363–1369
  11. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773–1777
  12. Zakarija A, Bandarenko N, Pandey DK, Auerbach A, Raisch DW, Kim B, et al. Clopidogrel-associated TTP: An update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004;35:533–537
  13. Strom BL. What is pharmacoepidemiology?. In:  Strom BL editors. Pharmacoepidemiology. ed 3. Chichester, UK: Wiley; 2000;p. 3–16
  14. Rothman KJ, Greenland S. Modern Epidemiology. ed 2. Philadelphia, PA: Lippincott Williams & Wilkins; 1998;
  15. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. New York, NY: Wiley; 1982;
  16. Papanikolaou PN, Christidi GD, Ioannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ. 2006;174:635–641
  17. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In:  Strom BL editors. Pharmacoepidemiology. ed 4. Chichester, UK: Wiley; 2005;p. 811–829
  18. International Agranulocytosis and Aplastic Anaemia Study. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. BMJ. 1988;297:262–265
  19. Kaufman DW, Kelly JP, Johannes CB, Sandler A, Harmon D, Stolley PD, et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood. 1993;82:2714–2718
  20. Kaufman DW, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia: The International Agranulocytosis and Aplastic Anemia Study. New York, NY: Oxford University Press; 1991;
  21. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia. 1997;38:1265–1269
  22. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004;297–317
  23. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006;199–204
  24. The International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia (A first report of their relation to drug use with special reference to analgesics). JAMA. 1986;256:1749–1757
  25. The design of a study of the drug etiology of agranulocytosis and aplastic anemia (A report from the International Agranulocytosis and Aplastic Anemia Study). Eur J Clin Pharmacol. 1983;24:833–836
  26. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84:937–945
  27. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12:1063–1073
  28. Csizmadi I, Collett J-P, Boivin J-F. Bias and confounding in pharmacoepidemiology. In:  Strom BL editors. Pharmacoepidemiology. ed 4. Chichester, UK: Wiley; 2005;p. 791–809
  29. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129:886–890
  30. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone S½urvey. JAMA. 2002;287:337–344
  31. Patterns of Medication Use in the United States 2006: A Report from the Slone Survey. Slone Epidemiology Center at Boston University, 2007 http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf(accessed December 4, 2007)
  32. Breslow NE, Day NE. Statistical methods in cancer research (Volume I—The analysis of case-control studies). IARC Sci Publ. 1980;5-338
  33. Cox DR, Oakes D. Analysis of Survival Data. London, UK: Chapman Hall; 1984;
  34. Breslow NE, Day NE. Statistical methods in cancer research (Volume II—The design and analysis of cohort studies). IARC Sci Publ. 1987;1-406
  35. Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, et al. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107:1299–1307
  36. Baumelou E, Guiguet M, Mary JY The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Epidemiology of aplastic anemia in France: A case-control study (I. Medical history and medication use). Blood. 1993;81:1471–1478
  37. Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia. 2006;47:1232–1236
  38. Myers MW, Vasilakis C, Kaufman MR, Jick H. Antihypertensive drugs and the risk of idiopathic aplastic anaemia. Br J Clin Pharmacol. 2000;49:604–608
  39. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–1727
  40. Shapiro S. Bias in the evaluation of low-magnitude associations: An empirical perspective. Am J Epidemiol. 2000;151:939–945
  41. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(suppl 3):3–7
  42. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: A clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15:33–48
  43. Clozaril (clozapine) (Prescribing Information). East Hanover, NJ: Novartis Pharmaceuticals; May 2005;

PII: S0037-1963(08)00067-X

doi: 10.1053/j.seminhematol.2008.04.007

Seminars in Hematology
Volume 45, Issue 3 , Pages 181-188 , July 2008

Article Tools

* Image Usage & Resolution